|
|
Line 42: |
Line 42: |
| | | |
| </article> | | </article> |
− |
| |
| <article class="col-xs-12 col-sm-12 col-md-10 col-md-offset-1" id="Strategies"> | | <article class="col-xs-12 col-sm-12 col-md-10 col-md-offset-1" id="Strategies"> |
| <h1>Strategies</h1> | | <h1>Strategies</h1> |
− | <div class="row"> | + | <div class="row" style="text-align:center;"> |
− | <div class="col-md-6">
| + | |
| <h2>BEVS</h2> | | <h2>BEVS</h2> |
| <img src="https://static.igem.org/mediawiki/2015/7/7d/Tec-Monterrey_Baculovirus_1.jpg" class="img-responsive"> | | <img src="https://static.igem.org/mediawiki/2015/7/7d/Tec-Monterrey_Baculovirus_1.jpg" class="img-responsive"> |
− | </div>
| |
− | <div class="col-md-6">
| |
| <p align="justify">Characterization of the widely used polyhedrin promoter (<a href="http://parts.igem.org/Part:BBa_K173400">BBa_K1734000</a>) and the confirmation of two secretion signals (<a href="http://parts.igem.org/Part:BBa_K1734001">BBa_K1734001</a>, <a href="http://parts.igem.org/Part:BBa_K1734002">BBa_K1734002</a>). All the work was confirmed by using the reporter gene Nanoluc (<a href="http://parts.igem.org/Part:BBa_K1734004">BBa_K1734004</a>)</p> | | <p align="justify">Characterization of the widely used polyhedrin promoter (<a href="http://parts.igem.org/Part:BBa_K173400">BBa_K1734000</a>) and the confirmation of two secretion signals (<a href="http://parts.igem.org/Part:BBa_K1734001">BBa_K1734001</a>, <a href="http://parts.igem.org/Part:BBa_K1734002">BBa_K1734002</a>). All the work was confirmed by using the reporter gene Nanoluc (<a href="http://parts.igem.org/Part:BBa_K1734004">BBa_K1734004</a>)</p> |
− | </div>
| |
| </div> | | </div> |
− | <div class="row"> | + | <div class="row" style="text-align:center;"> |
− | <div class="col-md-6">
| + | |
| <h2>STABLE</h2> | | <h2>STABLE</h2> |
| <img src="https://static.igem.org/mediawiki/2015/6/61/Tec-Monterrey_Stable_Line_1.jpg" class="img-responsive"> | | <img src="https://static.igem.org/mediawiki/2015/6/61/Tec-Monterrey_Stable_Line_1.jpg" class="img-responsive"> |
− | </div>
| |
− | <div class="col-md-6">
| |
| <p align="justify">Random genome integration to generate a stable cell line mediated by zeocin antibiotic resistance by selective pressure. The promoter OpIE2 (<a href="http://parts.igem.org/Part:BBa_K1734001">BBa_K1734001</a>) was used to test protein production.</p> | | <p align="justify">Random genome integration to generate a stable cell line mediated by zeocin antibiotic resistance by selective pressure. The promoter OpIE2 (<a href="http://parts.igem.org/Part:BBa_K1734001">BBa_K1734001</a>) was used to test protein production.</p> |
− | </div>
| |
| </div> | | </div> |
− | <div class="row"> | + | <div class="row" style="text-align:center;"> |
− | <div class="col-md-6">
| + | <h2>CRISP/Cas9</h2> |
− | <h2>CRISPR/Cas9</h2> | + | <img src="https://static.igem.org/mediawiki/2015/c/c2/Tec-Monterrey_Crispr_1.jpg" class="img-responsive"> |
− | <img src="https://static.igem.org/mediawiki/2015/c/c2/Tec-Monterrey_Crispr_1.jpg" class="img-responsive"> | + | |
− | </div>
| + | |
− | <div class="col-md-6">
| + | |
| <p align="justify">To prove the function of the CRISPR/Cas9 in the Sf9, we developed two constructs of our gRNA (<a href="http://parts.igem.org/Part:BBa_K1734012">BBa_K1734012</a>, <a href="http://parts.igem.org/Part:BBa_K1734013">BBa_K1734013</a>) to attenuate the Nanoluc’s luminescence in the stable cell line. These gRNAs are in the same plasmid that produces the Cas9 protein and a GFP protein as a fluorescent marker, having two separate plasmids. We will work with both pathways of CRISPR: nonhomologous end joining and homology-directed repair.</p> | | <p align="justify">To prove the function of the CRISPR/Cas9 in the Sf9, we developed two constructs of our gRNA (<a href="http://parts.igem.org/Part:BBa_K1734012">BBa_K1734012</a>, <a href="http://parts.igem.org/Part:BBa_K1734013">BBa_K1734013</a>) to attenuate the Nanoluc’s luminescence in the stable cell line. These gRNAs are in the same plasmid that produces the Cas9 protein and a GFP protein as a fluorescent marker, having two separate plasmids. We will work with both pathways of CRISPR: nonhomologous end joining and homology-directed repair.</p> |
− | </div>
| |
| </div> | | </div> |
| </article> | | </article> |